Published in Clin Cancer Res on October 02, 2015
Ockham's razor for the MET-driven invasive growth linking idiopathic pulmonary fibrosis and cancer. J Transl Med (2016) 1.38
Triple-negative breast cancer: challenges and opportunities of a heterogeneous disease. Nat Rev Clin Oncol (2016) 1.18
Phase II and Biomarker Study of Cabozantinib in Metastatic Triple-Negative Breast Cancer Patients. Oncologist (2016) 0.77
Recent developments and translational aspects in targeted therapy for metastatic breast cancer. ESMO Open (2016) 0.76
cMET inhibitor crizotinib impairs angiogenesis and reduces tumor burden in the C3(1)-Tag model of basal-like breast cancer. Springerplus (2016) 0.75
MET exon 14 juxtamembrane splicing mutations: clinical and therapeutical perspectives for cancer therapy. Ann Transl Med (2017) 0.75
Matriptase regulates c-Met mediated proliferation and invasion in inflammatory breast cancer. Oncotarget (2016) 0.75
Pathomimetic avatars reveal divergent roles of microenvironment in invasive transition of ductal carcinoma in situ. Breast Cancer Res (2017) 0.75
Live-Cell Imaging of Protease Activity: Assays to Screen Therapeutic Approaches. Methods Mol Biol (2017) 0.75
Stromal expression of miR-21 identifies high-risk group in triple-negative breast cancer. Am J Pathol (2014) 0.82
Miz1, a Novel Target of ING4, Can Drive Prostate Luminal Epithelial Cell Differentiation. Prostate (2016) 0.75